CoChat

Amyloid PET Imaging in Lewy Body Disorders

Open access
Donaghy, Paul, Thomas, Alan J., O'Brien, John T. · 2015 · The American Journal of Geriatric Psychiatry
Cited by 117

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Lewy body (LB) disorders, including Parkinson disease (PD), Parkinson disease dementia (PDD), and dementia with Lewy bodies (DLB), are the second most common type of neurodegenerative dementia. Although the pathological hallmarks of LB disorders are Lewy bodies and Lewy neurites, cortical amyloid-beta (Aβ) deposition is also often seen. The relationship between Aβ pathology and dementia in LB disorders is unclear. Recently, positron emission tomography Aβ ligands have been developed that enable in vivo imaging of Aβ. In this paper we review amyloid imaging studies in LB disorders. LB disorders are associated with lower mean cortical Aβ ligand binding compared with Alzheimer disease. In DLB and PDD many subjects have normal levels of cortical Aβ, though a subset show increased Aβ ligand binding. Those with DLB show greater ligand binding than PDD; binding does not appear to be increased in PD without dementia. Cortical Aβ deposition may be a factor in the development of cognitive impairment in some cases of dementia in LB disorders. Amyloid imaging is of limited use in the diagnosis of LB disorders but Aβ deposition may predict the future development of dementia in PD. Reports of correlation between Aβ deposition and symptom profile, severity, and progression have been inconsistent. Some results suggest a synergistic interaction between Aβ and α-synuclein. Interpretation of the current evidence is hampered by differing methodologies across studies and small sample sizes. Large, prospective longitudinal studies are needed to clarify the association of Aβ with symptom development, progression, severity, and treatment response in LB disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jagp.2013.03.001

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 55

  1. Stevens, 2002, Islington study of dementia subtypes in the community, Br J Psychiatry, 180, 270, 10.1192/bjp.180.3.270 · DOI · Paper page
  2. McKeith, 2009, Commentary: DLB and PDD: the same or different? Is there a debate?, Int Psychogeriatr, 21, 220, 10.1017/S1041610208008624 · DOI
  3. Kovari, 2009, Neuropathology of Lewy body disorders, Brain Res Bull, 80, 203, 10.1016/j.brainresbull.2009.06.018 · DOI
  4. Merdes, 2003, Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies, Neurology, 60, 1586, 10.1212/01.WNL.0000065889.42856.F2 · DOI · Paper page
  5. Weisman, 2007, In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution, Neurology, 69, 356, 10.1212/01.wnl.0000266626.64913.0f · DOI · Paper page
  6. Del Ser, 2001, Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load, Alzheimer Dis Assoc Disord, 15, 31, 10.1097/00002093-200101000-00005 · DOI · Paper page
  7. Fujishiro, 2010, Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia, Neurosci Lett, 486, 19, 10.1016/j.neulet.2010.09.036 · DOI
  8. Selikhova, 2009, A clinico-pathological study of subtypes in Parkinson's disease, Brain, 132, 2947, 10.1093/brain/awp234 · DOI · Paper page
  9. Aarsland, 2004, Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?, J Geriatr Psychiatry Neurol, 17, 137, 10.1177/0891988704267470 · DOI · Paper page
  10. Jellinger, 2003, Clinical and neuropathological correlates of Lewy body disease, Acta Neuropathol, 106, 188, 10.1007/s00401-003-0721-2 · DOI
  11. Pletnikova, 2005, Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases, Neurobiol Aging, 26, 1183, 10.1016/j.neurobiolaging.2004.10.006 · DOI · Paper page
  12. Rowe, 2011, Brain amyloid imaging, J Nucl Med, 52, 1733, 10.2967/jnumed.110.076315 · DOI · Paper page
  13. Sojkova, 2011, In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults, Arch Neurol, 68, 232, 10.1001/archneurol.2010.357 · DOI · Paper page
  14. Quigley, 2011, PET imaging of brain amyloid in dementia: a review, Int J Geriatr Psychiatry, 26, 991, 10.1002/gps.2640 · DOI · Paper page
  15. Rosenberg, 2013, Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography, Am J Geriatr Psychiatry, 21, 272, 10.1016/j.jagp.2012.11.016 · DOI
  16. Edison, 2008, Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography, J Neurol Neurosurg Psychiatry, 79, 1331, 10.1136/jnnp.2007.127878 · DOI · Paper page
  17. Gomperts, 2012, Brain amyloid and cognition in Lewy body diseases, Mov Disord, 27, 965, 10.1002/mds.25048 · DOI · Paper page
  18. Kantarci, 2012, Multimodality imaging characteristics of dementia with Lewy bodies, Neurobiol Aging, 33, 2091, 10.1016/j.neurobiolaging.2011.09.024 · DOI · Paper page
  19. Foster, 2010, Amyloid imaging of Lewy body-associated disorders, Mov Disord, 25, 2516, 10.1002/mds.23393 · DOI · Paper page
  20. Villemagne, 2011, Amyloid Imaging with F-18-Florbetaben in Alzheimer Disease and Other Dementias, J Nucl Med, 52, 1210, 10.2967/jnumed.111.089730 · DOI · Paper page
  21. Claassen, 2011, Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy, Parkinsonism Relat Disord, 17, 160, 10.1016/j.parkreldis.2010.12.006 · DOI
  22. Maetzler, 2008, [11C]PIB binding in Parkinson's disease dementia, Neuroimage, 39, 1027, 10.1016/j.neuroimage.2007.09.072 · DOI
  23. Petrou, 2012, Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia, Neurology, 79, 1161, 10.1212/WNL.0b013e3182698d4a · DOI · Paper page
  24. Maetzler, 2009, Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics, Neurobiol Dis, 34, 107, 10.1016/j.nbd.2008.12.008 · DOI · Paper page
  25. Shimada H, Shinotoh H, Hirano S, et al: Beta-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28:169–175 · DOI · Paper page
  26. Jokinen, 2010, [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia, Parkinsonism Relat Disord, 16, 666, 10.1016/j.parkreldis.2010.08.021 · DOI
  27. Johansson, 2008, [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results, Parkinsonism Relat Disord, 14, 345, 10.1016/j.parkreldis.2007.07.010 · DOI
  28. Gomperts, 2013, Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia, Neurology, 80, 85, 10.1212/WNL.0b013e31827b1a07 · DOI · Paper page
  29. Graff-Radford, 2012, Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies, Brain, 135, 2470, 10.1093/brain/aws173 · DOI · Paper page
  30. Sinha, 2012, Biomarkers in dementia with Lewy bodies: a review, Int J Geriatr Psychiatry, 27, 443, 10.1002/gps.2749 · DOI
  31. Burke, 2011, Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography, Brain, 134, 1647, 10.1093/brain/awr089 · DOI · Paper page
  32. Bacskai, 2007, Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report, Arch Neurol, 64, 431, 10.1001/archneur.64.3.431 · DOI · Paper page
  33. Burack, 2010, In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia, Neurology, 74, 77, 10.1212/WNL.0b013e3181c7da8e · DOI · Paper page
  34. Kantarci, 2012, Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies, Neurobiol Aging, 33, 878, 10.1016/j.neurobiolaging.2010.08.007 · DOI · Paper page
  35. Ikonomovic, 2012, Early AD pathology in a C-11 PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study, Acta Neuropathol, 123, 433, 10.1007/s00401-012-0943-2 · DOI · Paper page
  36. Harding, 2001, Cortical Lewy body pathology in the diagnosis of dementia, Acta Neuropathol, 102, 355, 10.1007/s004010100390 · DOI · Paper page
  37. Jellinger, 2008, Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease, Acta Neuropathol, 115, 427, 10.1007/s00401-008-0347-5 · DOI · Paper page
  38. Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, 134, 1493, 10.1093/brain/awr031 · DOI · Paper page
  39. Mirra, 1991, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
  40. Kempster, 2007, Patterns of levodopa response in Parkinson's disease: a clinico-pathological study, Brain, 130, 2123, 10.1093/brain/awm142 · DOI · Paper page
  41. Jellinger, 2002, Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease, J Neural Transm, 109, 329, 10.1007/s007020200027 · DOI · Paper page
  42. Aarsland, 2005, Neuropathology of dementia in Parkinson's disease: a prospective, community-based study, Ann Neurol, 58, 773, 10.1002/ana.20635 · DOI · Paper page
  43. Lashley, 2008, Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients, Acta Neuropathol, 115, 417, 10.1007/s00401-007-0336-0 · DOI · Paper page
  44. Ballard, 2004, Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies, Am J Psychiatry, 161, 843, 10.1176/appi.ajp.161.5.843 · DOI · Paper page
  45. Serby, 2003, Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease, Am J Geriatr Psychiatry, 11, 371, 10.1176/appi.ajgp.11.3.371 · doi:10.1176/appi.ajgp.11.3.371
  46. Kraybill, 2005, Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both, Neurology, 64, 2069, 10.1212/01.WNL.0000165987.89198.65 · DOI · Paper page
  47. Mattila, 2000, Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease, Acta Neuropathol, 100, 285, 10.1007/s004019900168 · DOI · Paper page
  48. Braak, 2005, Cognitive status correlates with neuropathologic stage in Parkinson disease, Neurology, 64, 1404, 10.1212/01.WNL.0000158422.41380.82 · DOI · Paper page
  49. Sabbagh, 2009, Parkinson disease with dementia: comparing patients with and without Alzheimer pathology, Alzheimer Dis Assoc Disord, 23, 295, 10.1097/WAD.0b013e31819c5ef4 · DOI · Paper page
  50. Moghbel, 2012, Amyloid-beta imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?, Eur J Nucl Med Mol Imaging, 39, 202, 10.1007/s00259-011-1960-4 · DOI
  51. Villemagne, 2012, A beta imaging: feasible, pertinent, and vital to progress in Alzheimer's disease, Eur J Nucl Med Mol Imaging, 39, 209, 10.1007/s00259-011-2045-0 · DOI
  52. Svedberg, 2009, [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients, Neurochem Int, 54, 347, 10.1016/j.neuint.2008.12.016 · DOI
  53. Herholz, 2011, Clinical amyloid imaging in Alzheimer's disease, Lancet Neurol, 10, 667, 10.1016/S1474-4422(11)70123-5 · DOI · Paper page
  54. Fujishiro, 2008, Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases, J Neuropathol Exp Neurol, 67, 649, 10.1097/NEN.0b013e31817d7a1d · DOI · Paper page
  55. Burton, 2009, Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis, Brain, 132, 195, 10.1093/brain/awn298 · DOI · Paper page

Cited by

See all 117

Metadata

Authors
Donaghy, P., Thomas, A. J., & O'Brien, J. T.
Venue
The American Journal of Geriatric Psychiatry
Publisher
Elsevier BV
Published
2015-01
Volume
23
Issue
1
Pages
23-37
ISSN
1064-7481 (ISSN-L)
OpenAlex
W2092013637
Cited by
117
References
19
FWCI
6.80
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Institute for Health Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid PET Imaging in Lewy Body Disorders. https://app.cochat.ai/papers/10.1016/j.jagp.2013.03.001
The paper
Donaghy, P., Thomas, A. J., & O'Brien, J. T. (2015). Amyloid PET Imaging in Lewy Body Disorders. The American Journal of Geriatric Psychiatry. https://doi.org/10.1016/j.jagp.2013.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.